非侵入AI超声脑机接口公司华超神控完成2亿元Pre-A轮融资 红杉、云启领投

Overall: Huachao Shenkong has completed a 200 million RMB Pre-A funding round, signaling that brain-computer interfaces are moving from concept to industrialization. In the future, ordinary people may be able to improve brain-related health issues through non-invasive devices.

1. Core takeaways: The company focuses on non-invasive ultrasound brain-computer interfaces, which can reach deep brain regions without opening the skull. Its products span scientific research, clinical, and consumer scenarios, with the consumer line explicitly targeting improvements in sleep, mood, and focus.

2. Investment signal: The round was led by Sequoia China and Qiyun Capital, bringing total funding to nearly 300 million RMB since inception. Global capital is also pouring into the ultrasound BCI route, indicating the industry is on the verge of a boom.

3. Risk note: The company has not yet disclosed medical device registration certificates, product revenue, or order data, so it still has a way to go before entering hospitals and households. Going forward, the key is whether clinical safety and efficacy results are replicable.

Overall: Brand owners can draw inspiration from Huachao Shenkong's positioning, product roadmap, and funding trajectory for building tech brands and anticipating consumer trends.

1. Brand positioning: Huachao Shenkong defines itself as a benchmark enterprise in non-invasive AI brain-computer interfaces, with plans to grow into a Neuro AI company built on brain data. This suggests that brand owners should capture category mindshare early and use clear technical labels and long-term vision to build differentiation.

2. Product development and scenario segmentation: The company uses its research line to explore how the brain works, its clinical line to address treatment, and its consumer line to bring technology into daily life, targeting sleep, mood, and focus scenarios. Brand owners can borrow this product matrix logic and communicate with users through scenario-based language, focusing on high-frequency health needs.

3. Trust endorsement: Leading capital firms such as Sequoia, Qiyun, and Matrix Partners continue to add investment, with existing shareholders following on, creating strong credibility. In addition, serving universities and hospitals builds professional reputation, which will help reduce the cost of brand trust when expanding into the consumer market.

Overall: Sellers should watch the brain-computer interface market as a high-growth opportunity. The non-invasive ultrasound route is attracting concentrated capital, with opportunities across research, clinical, and consumer segments.

1. Growth market: Huachao Shenkong completed a 200 million RMB Pre-A round; peer company Gestalt Technology raised 570 million RMB within six months; OpenAI also invested in overseas ultrasound BCI company Merge Labs. The industry is in an early explosive stage.

2. Changing consumer demand: The planned consumer products focus on sleep, mood, and focus, reflecting rising public demand for non-invasive brain health solutions. Related device retail and health service offerings could form new categories.

3. Risk note: Most companies have not yet reached commercial maturity. Huachao Shenkong has not disclosed medical device registration, product revenue, or customer order data. Sellers need to assess product maturity, compliance, and after-sales risks before entering.

4. Opportunity areas: Watch for research equipment procurement, clinical trial support services, future distribution of consumer products, and regional supply chain and cooperation needs from Gestalt's R&D and production base in Chengdu.

Overall: Factories can identify new opportunities in hardware production and design from the BCI boom, especially supply chain demand for ultrasound equipment and consumer-grade wearables.

1. Production demand: Huachao Shenkong has launched a closed-loop BCI system, an AI platform for ultrasound neuromodulation parameter interaction, and Cortex Atlas, involving hardware such as ultrasound transducers, signal acquisition modules, and wearable devices. Factories with precision manufacturing capabilities can look at OEM opportunities for non-invasive BCI devices.

2. Mass production plans: Peer company Gestalt Technology is building an R&D and production conversion base in Chengdu, indicating the industry is moving from lab to mass production. Factories with medical device production qualifications, ultrasonic component processing, and EEG sensor manufacturing capabilities could enter the supply chain.

3. Design direction: Consumer products are planned for sleep, mood, and focus scenarios, requiring miniaturized, portable, and comfortable devices. Factories can prepare in advance in flexible materials, low-power components, and integrated manufacturing processes to match future demand.

4. Digitalization insights: The company emphasizes AI infrastructure and a big data foundation, suggesting factories should advance digital and intelligent production, use data capabilities to build manufacturing barriers, and participate in the BCI hardware ecosystem.

Overall: Service providers can observe the development trends of the brain-computer interface industry and identify solution opportunities from Huachao Shenkong's technology layout and product system.

1. Industry trends: BCI is expanding from invasive electrode routes to non-invasive ultrasound routes. The combination of ultrasound neuromodulation, multimodal brain reading, and AI neural decoding has become a hot portfolio, with Huachao Shenkong, Gestalt, Nudge, and Merge Labs all raising substantial funding.

2. Customer pain points: Research customers need to compare, select, and adjust ultrasound parameters and organize evidence on brain regions and targets. Clinical customers need replicable safety and efficacy results. Consumer-end users need non-invasive improvements in sleep, mood, and focus.

3. Solution opportunities: There are opportunities to provide data annotation, algorithm optimization, clinical data management, and AI infrastructure services around platforms like the ultrasound parameter interaction AI platform and Cortex Atlas. There is also room to offer regulatory filing, clinical trial management, and compliance consulting to early-stage companies.

Overall: Marketplace/platform operators should pay attention to the demand for data and technology platforms in the BCI industry, as well as the platform-building implications of Huachao Shenkong's latest moves.

1. Platform demand: Huachao Shenkong proposes to become a Neuro AI company built on brain data, with future AI learning from the human brain itself. This will create platform-level needs for brain data collection, storage, processing, and circulation, while raising data privacy and security challenges.

2. Platform approach: The company has launched a non-invasive closed-loop BCI system, an AI platform for ultrasound neuromodulation parameter interaction, and Cortex Atlas, which handle stimulation/acquisition, parameter adjustment, and knowledge organization, respectively. This forms a closed loop of hardware + AI platform + knowledge base, a vertical platform model platform operators can learn from.

3. Merchant recruitment and operations: BCI devices have not yet obtained medical device registration, and product revenue and orders are undisclosed. Platform operators should carefully assess compliance and after-sales before introducing such products, and should track subsequent clinical research results and hospital procurement progress.

4. Risk avoidance: Industry capital heat is high but commercial maturity is low. Platform operators should require companies to provide sufficient safety and efficacy data to avoid liability risks from low-maturity products.

Overall: Researchers can observe new industry trends and related research questions in ultrasound brain-computer interfaces from Huachao Shenkong's funding and product pipeline.

1. Industry trends: Capital has expanded from invasive electrode routes to non-invasive ultrasound routes. Huachao Shenkong, Gestalt, Nudge, and Merge Labs have all raised substantial early-stage funding, showing that the combination of ultrasound devices and AI is becoming a new focus for industrialization.

2. Core issues: The company's research line explores how the brain works, the clinical line explores how to treat diseases, and the consumer line explores interventions for sleep, mood, and focus. However, safety and efficacy still need to be verified. No medical device registration, product revenue, or order data have been disclosed. Whether researcher-initiated studies can produce replicable results is key.

3. Policy and standards implications: Non-invasive BCI devices entering hospitals and households face issues such as registration approval, clinical research standards, and brain data privacy. It is necessary to build a database of replicable clinical evidence and ultrasound parameter standards to support industrialization.

4. Business model observation: The company is simultaneously pursuing scientific equipment sales, clinical translation, and consumer-scenario reserves, with plans to train next-generation AI using brain data, forming a data-algorithm-application loop. It is worth tracking how the scale and quality of its data affect the building of its AI foundation.